Leading Autoimmune Diseases to Undergo Robust Improvement in Treatment by Major Pharma Companies

Immunological and Autoimmune Disorders

Allergy Diagnostics: Unraveling the Science, Ma...

Allergies are on the rise globally, affecting millions of people and significantly impacting their quality of life. The ability to accurately diagnose and manage allergies is crucial for both patie...

Oct 18, 2023

Immunomodulators Market and Key Applications
Harnessing the Power of Immunomodulators: Applications and Implications

The human immune system has a magnificent defense system that works continuously to protect the body from numerous infections and outside invaders. Maintaining a healthy immune response through the intricate interplay of cells, chemicals, and signaling pathways is essential for general health and well-being. Immuno...

Find More
Pharma News for Amgen, Anaptys, Sanofi, Boehringer
Amgen to Acquire Horizon Therapeutics; Sanofi and Teva Announce Collaboration; Boehringer Obesity Drug Trial Update; FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL; Anaptys Announces Phase 3 Clinical Trial Results of Imsidolimab; Orphan Drug Designation to GC Biopharma’s GC1126A

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment Sanofi and Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the United States, have announced a collaboration to co-develop and co-commercialize asset TEV'574, which is currently in Phase ...

Find More
Pharma News for AbbVie, Novartis, Avenge Bio, Eli Lilly
AbbVie Presents Phase III CANOVA Study Results; Novartis’ Iptacopan Shows Promise in Phase III Study; Fast Track Designation to AVB-001 for R/R Platinum-Resistant Ovarian Cancer; FDA Issues Complete Response Letter for Lebrikizumab; Nedosiran Approveed for Primary Hyperoxaluria Type 1; Orphan Drug Designation to BDC-1001 for Gastric Cancers

AbbVie Presents Results from Phase III CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma AbbVie has released findings from its Phase III CANOVA trial, which assessed the safety and effectiveness of venetoclax (marketed as VENCLEXTA®/VENCLYXTO®) in combination with dexamethasone ...

Find More

More Views & Analysis

Pharma News for BMS, Alnylam, MaaT Pharma
BMS’s LPA1 Antagonist; Alnylam’s KARDIA-1 Phase 2 Study; Day One Biopharma Sought FDA Approval for Tovorafenib; EMA Orphan Drug Designation to MaaT Pharma’s MaaT033; Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole + Sertraline; Phase III CheckMate – 227 Trial Show Durable, Long-Term Survival with Opdivo Plus Yervoy

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase II Study BMS-986278, a potential first-in-class oral lysophosphatidic acid receptor 1 (LPA1) antagonist, was studied in patients with progressive pulmonary fibrosis (PPF)...

Find More

Pharma News for Biogen, Astellas, Ascentage
FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

FDA Approves ZURZUVAE, the First and Only Oral Treatment Approved for Women with Postpartum Depression Biogen Inc. and Sage Therapeutics, Inc. announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for individuals with postpartum depression (PPD). ZURZUVAE is the first and only 14-day oral, once-daily t...

Find More

Nutricosmetics Market Outlook
Evaluating the Evolving Trends in the Nutricosmetics Market: The Intersection of Nutrition and Skincare

The desire for natural beauty that can improve one's health and appearance without having any negative side effects is rising as consumers are becoming more cautious about the food they eat and the products they introduce into their bodies. Nutricosmetics are one such category of product that fit with the modern cu...

Find More

graft-versus-host-disease-gvhd-treatment
Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...

Find More

Gene Therapies for Dystrophic Epidermolysis Bullosa
Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Dystrophic epidermolysis bullosa (DEB) is an inherited disorder caused by changes in the COL7A1 gene. In this rare condition, blisters form on the skin and the moist inner lining of some organs and body cavities. Depending upon the nature of the inheritance pattern, dystrophic epidermolysis bullosa is divided into ...

Find More

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier
Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults Pfizer Inc. announced that the FDA has authorized ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory...

Find More

An inflammatory disease of large intestine, Ulcerative Colitis (UC), is approached with therapies th.....

Find More

Past decades have witnessed a shift in the focus of researchers and pharma companies towards tailori.....

Find More

Peanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....

Find More

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare form of neoplasm, generally .....

Find More

A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....

Find More

Nonalcoholic steatohepatitis (NASH) affects individuals slowly and progressively. Presently, there e.....

Find More